Target Organ Damage

2

Review clinical trials related to Target Organ Damage. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Common Carotid Artery-Renal Artery-Femoral Artery Survey for Hypertension

To evaluate both sides of the common carotid artery, renal artery, and femoral artery in Hypertension patient that cause of systemic arterial hypertension and/or the effects of target organ damage, both structural and functional markers.

Participants needed: 100
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: DejthidaNathaphongUpdated: Aug 12, 2026Locations: 1
Eligibility criteria

Adults ≥18 years with diagnosed hypertension by a clinician, both untreated and... [+4]

Fatal pathology and imaging [+4]

Status: Recruiting

GlycOxiTOD: Multimodal Vascular and Target-Organ Damage Registry

The goal of the GlycOxiTOD observational registry is to improve the early detection and characterization of vascular and other target-organ damage in adults at increased cardiovascular risk. Target-organ damage (TOD) means changes in the arteries, heart, kidneys, or other organs that may develop before cardiovascular symptoms or events occur. The registry studies how blood pressure, arterial function, vascular imaging, metabolic and glycoxidative markers, and non-invasive optical signals are related to this early damage. The main questions are: * Which clinical, blood pressure, imaging, and laboratory markers are associated with vascular and other target-organ damage? * Can photoplethysmography, a non-invasive optical technique that records changes in blood flow, identify abnormal arterial features? * Are new devices, measurement procedures, and signal-analysis methods technically valid, reliable, and reproducible when compared with established clinical methods? * Can combinations of clinical, imaging, laboratory, and device-derived measurements improve cardiovascular risk assessment? * How do vascular abnormalities and target-organ damage change during follow-up? Researchers will not assign any treatment as part of this observational registry. Participants will receive assessments that may include: * Clinical and cardiovascular risk evaluation * Office and 24-hour ambulatory blood pressure measurements * Blood and urine tests for metabolic, glycation, oxidative stress, and inflammatory markers * Non-invasive vascular ultrasound and arterial function measurements * Optical photoplethysmography recordings from peripheral or cervical arterial sites * Skin measurement of advanced glycation end products * Retinal imaging, when available * Repeated measurements to assess the reliability and reproducibility of selected devices and procedures * Follow-up using clinical visits and medical records to identify changes in target-organ damage and cardiovascular events The registry provides a shared clinical research platform for studies on hypertension, vascular imaging, arterial biomechanics, biomarkers, optical technologies, and the technical and methodological validation of non-invasive cardiovascular devices. Its overall aim is to support the development of reliable tools for early cardiovascular risk assessment and prevention.

Participants needed: 1,000
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Complejo Hospitalario Universitario de SantiagoUpdated: Aug 5, 2026Locations: 1Duration: 5 Years
Eligibility criteria

Age 18 years or older. [+10]

Inability or unwillingness to provide written informed consent. [+3]